Ecnoglutide, a novel once-weekly injection for type 2 diabetes management, works as well as dulaglutide (a commonly ...

Dulaglutide injection should be given subcutaneously in the abdomen, thigh or upper arm once e every week at any time of the day. The initial dose is 0.75 mg once a week.

NEW ORLEANS — Young people with type 2 diabetes taking the once-weekly GLP-1 receptor agonist dulaglutide had a decrease in HbA1c at 26 weeks without a significant change in BMI, according to ...

Trulicity (dulaglutide), a once-weekly subcutaneous injection, has been approved by the U.S. Food and Drug Administration to improve glycemic control in adults with type 2 diabetes along with diet ...

Dulaglutide injection is used as an add-on therapy to diet and exercise to decrease blood glucose levels in adults with type 2 diabetes mellitus. More info about Dulaglutide ...

Dulaglutide injections are still in shortage, though manufacturers report all presentations available. Liraglutide injections also remain in shortage with two presentations available and three in ...

Results Interviews were completed by 201 participants (52.7% male; mean age = 58.7). Preferences between treatment processes varied widely. Mean utilities were 0.890 for simple oral, 0.880 for oral ...

The US Food and Drug Administration (FDA) has approved dulaglutide (Trulicity, Eli Lilly & Co), as a once-weekly injection for the treatment of type 2 diabetes. A member of the glucagonlike ...

At 26 weeks, HbA 1c dropped 1.42% with dulaglutide and 1.36% with liraglutide. The 0.06% difference met the prespecified 0.4% noninferiority margin.

INDIANAPOLIS, Nov. 25, 2014 /PRNewswire/ -- Eli Lilly and Company announced today that the European Commission granted marketing authorisation for Trulicity ® (dulaglutide) solution for injection.